In light of the recent exciting and innovative developments in ITM Isotopen Technologies München SE (“ITM”), the underlying investment within ITM AG Investment LP and ITM AG Investment Trust, Portland Investment Counsel Inc. has created links to brief summaries for our investors to highlight some notable milestones and important progress. Within these summaries, we have also included links to the full articles or releases for further details.

• October 18, 2021: ITM and CNL Sign Memorandum of Understanding
• September 21, 2021: ITM Completes Conversion into a European Company
• September 13, 2021: Joint Venture of ITM and Chengdu Gaotong Isotope Co. Ltd.
• July 6, 2021: ITM Announced Appointment of Dr. Sabine Daugelat as Chief Operating Officer
• June 10, 2021: ITM Announced Close of a Private Equity Financing Raising a Total of US$30 Million
• June 3, 2021: Targeted Radio-Ligand Therapy Significantly Improves Overall Survival
• May 5, 2021: ITM Announces Establishment of a Chinese Subsidiary in China
• April 26, 2021: ITM’s Successful Close of Convertible Loan
• April 10, 2021: ITM Presents Design for Ongoing Phase III COMPETE Trial
• March 26, 2021: Radiogland Therapy Improves Survival of Prostate Cancer
• March 18, 2021: ITM Global Supplier of High Quality Medical RadioisotopesFor more information please contact Chris Wain-Lowe, Dragos Berbecel, or Kyle Ostrander. Sincerely,

Christopher Wain-Lowe Dragos Berbecel, MBA, CFA Portland Investment Counsel Portland Investment Counsel Chief Investment Officer, Portfolio Manager
Executive VP& Portfolio Manager dberbecel@portlandic.com clowe@portlandic.com

Kyle Ostrander, CFA
Portland Investment Counsel Portfolio Manager kostrander@portlandic.com

HEAD OFFICE
1375 Kerns Road, Suite 100
Burlington, ON L7P 4V7
Phone: (905) 331-4250 ext. 4232 or 4234

TORONTO OFFICE:
100 King Street West, Suite 5708 Toronto, ON M5X 1B1
Phone: 416-304-9440 ext. 2004